Connor, Clark & Lunn Investment Management Ltd.

Position in ENTA — Enanta Pharmaceuticals Inc

CIK 1596800 VANCOUVER, A1

Position in ENTA

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$1,588,336

-$50,214 QoQ

Shares Held

125,759

+21.0% QoQ

Ownership

0.432%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2020

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $706,217,766 across 100 Biotechnology names. ENTA ranks #61 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,588,336	125,759	+21.0%	Shares	Sole	2026-05-11
2025-12-31	$1,638,550	103,903	+34.1%	Shares	Sole	2026-02-10
2025-09-30	$927,746	77,506	+423.8%	Shares	Sole	2025-11-13
2025-06-30	$111,857	14,796	-51.4%	Shares	Sole	2025-08-07
2025-03-31	$168,166	30,465	+23.7%	Shares	Sole	2025-05-12
2024-12-31	$141,657	24,636	+109.3%	Shares	Sole	2025-02-10
2024-09-30	$121,916	11,768	-73.6%	Shares	Sole	2024-11-08
2024-03-31	$779,222	44,629	+7.9%	Shares	Sole	2024-05-09
2023-12-31	$389,244	41,365	+709.5%	Shares	Sole	2024-02-09
2022-09-30	$265,055	5,110	-48.4%	Shares	Sole	2022-11-10
2020-06-30	$497,631	9,911	—	Shares	Sole	2020-08-13
No filing history on record for this holder in this stock.